Does the media prefer ICLR or CRL?

In the previous week, Charles River Laboratories International had 19 more articles in the media than Icon. MarketBeat recorded 27 mentions for Charles River Laboratories International and 8 mentions for Icon. Icon's average media sentiment score of 0.99 beat Charles River Laboratories International's score of 0.96 indicating that Icon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 14 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TECH or CRL?

In the previous week, Charles River Laboratories International had 21 more articles in the media than Bio-Techne. MarketBeat recorded 27 mentions for Charles River Laboratories International and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.32 beat Charles River Laboratories International's score of 0.96 indicating that Bio-Techne is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 14 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IQV or CRL?

In the previous week, Charles River Laboratories International had 4 more articles in the media than IQVIA. MarketBeat recorded 27 mentions for Charles River Laboratories International and 23 mentions for IQVIA. IQVIA's average media sentiment score of 1.06 beat Charles River Laboratories International's score of 0.96 indicating that IQVIA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IQVIA 16 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Charles River Laboratories International 14 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Charles River Laboratories International (CRL) Competitors

$266.95 -0.54 (-0.20%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$267.38 +0.44 (+0.16%)

As of 08/7/2026 07:34 PM Eastern

Compare

CRL vs. ICLR, TECH, A, IQV, and RVTY

Should you buy Charles River Laboratories International stock or one of its competitors? MarketBeat compares Charles River Laboratories International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Charles River Laboratories International include Icon (ICLR), Bio-Techne (TECH), Agilent Technologies (A), IQVIA (IQV), and Revvity (RVTY). These companies are all part of the "life sciences tools & services" industry.

How does Charles River Laboratories International compare to Icon?

Icon (NASDAQ:ICLR) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Icon has a net margin of 3.99% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Icon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Icon has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

In the previous week, Charles River Laboratories International had 19 more articles in the media than Icon. MarketBeat recorded 27 mentions for Charles River Laboratories International and 8 mentions for Icon. Icon's average media sentiment score of 0.99 beat Charles River Laboratories International's score of 0.96 indicating that Icon is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.6% of Icon shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Icon has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.53	$229.34M	$4.26	38.62
Charles River Laboratories International	$4.02B	3.17	-$144.34M	-$4.85	N/A

Icon currently has a consensus price target of $170.40, indicating a potential upside of 3.58%. Charles River Laboratories International has a consensus price target of $246.69, indicating a potential downside of 7.59%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Icon beats Charles River Laboratories International on 9 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Bio-Techne has a net margin of 9.05% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	9.05%	13.57%	10.66%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Charles River Laboratories International had 21 more articles in the media than Bio-Techne. MarketBeat recorded 27 mentions for Charles River Laboratories International and 6 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.32 beat Charles River Laboratories International's score of 0.96 indicating that Bio-Techne is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bio-Techne has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.28	$73.40M	$0.69	104.77
Charles River Laboratories International	$4.02B	3.17	-$144.34M	-$4.85	N/A

Bio-Techne currently has a consensus price target of $68.08, indicating a potential downside of 5.83%. Charles River Laboratories International has a consensus price target of $246.69, indicating a potential downside of 7.59%. Given Bio-Techne's higher possible upside, equities research analysts clearly believe Bio-Techne is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	1 Sell rating(s)	13 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.12
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

99.0% of Bio-Techne shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Bio-Techne shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bio-Techne beats Charles River Laboratories International on 9 of the 15 factors compared between the two stocks.

How does Charles River Laboratories International compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Agilent Technologies has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market.

Agilent Technologies currently has a consensus target price of $159.35, suggesting a potential upside of 9.12%. Charles River Laboratories International has a consensus target price of $246.69, suggesting a potential downside of 7.59%. Given Agilent Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Agilent Technologies is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Agilent Technologies has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agilent Technologies	$6.95B	5.94	$1.30B	$4.98	29.32
Charles River Laboratories International	$4.02B	3.17	-$144.34M	-$4.85	N/A

98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Charles River Laboratories International had 19 more articles in the media than Agilent Technologies. MarketBeat recorded 27 mentions for Charles River Laboratories International and 8 mentions for Agilent Technologies. Agilent Technologies' average media sentiment score of 1.05 beat Charles River Laboratories International's score of 0.96 indicating that Agilent Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agilent Technologies	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agilent Technologies has a net margin of 19.55% compared to Charles River Laboratories International's net margin of -5.96%. Agilent Technologies' return on equity of 24.33% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agilent Technologies	19.55%	24.33%	12.99%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Summary

Agilent Technologies beats Charles River Laboratories International on 13 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to IQVIA?

IQVIA (NYSE:IQV) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

In the previous week, Charles River Laboratories International had 4 more articles in the media than IQVIA. MarketBeat recorded 27 mentions for Charles River Laboratories International and 23 mentions for IQVIA. IQVIA's average media sentiment score of 1.06 beat Charles River Laboratories International's score of 0.96 indicating that IQVIA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IQVIA	16 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

IQVIA has a net margin of 8.10% compared to Charles River Laboratories International's net margin of -5.96%. IQVIA's return on equity of 30.25% beat Charles River Laboratories International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IQVIA	8.10%	30.25%	6.54%
Charles River Laboratories International	-5.96%	15.75%	6.51%

IQVIA has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

IQVIA presently has a consensus target price of $241.88, suggesting a potential upside of 1.64%. Charles River Laboratories International has a consensus target price of $246.69, suggesting a potential downside of 7.59%. Given IQVIA's stronger consensus rating and higher possible upside, equities research analysts clearly believe IQVIA is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IQVIA	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

89.6% of IQVIA shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 1.7% of IQVIA shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

IQVIA has higher revenue and earnings than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IQVIA	$16.31B	2.40	$1.36B	$8.06	29.53
Charles River Laboratories International	$4.02B	3.17	-$144.34M	-$4.85	N/A

Summary

IQVIA beats Charles River Laboratories International on 13 of the 17 factors compared between the two stocks.

How does Charles River Laboratories International compare to Revvity?

Revvity (NYSE:RVTY) and Charles River Laboratories International (NYSE:CRL) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

In the previous week, Charles River Laboratories International had 6 more articles in the media than Revvity. MarketBeat recorded 27 mentions for Charles River Laboratories International and 21 mentions for Revvity. Charles River Laboratories International's average media sentiment score of 0.96 beat Revvity's score of 0.89 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	8 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Charles River Laboratories International	14 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revvity has a net margin of 8.16% compared to Charles River Laboratories International's net margin of -5.96%. Charles River Laboratories International's return on equity of 15.75% beat Revvity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Charles River Laboratories International	-5.96%	15.75%	6.51%

Revvity has higher earnings, but lower revenue than Charles River Laboratories International. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	4.48	$241.20M	$2.10	54.67
Charles River Laboratories International	$4.02B	3.17	-$144.34M	-$4.85	N/A

86.7% of Revvity shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Revvity currently has a consensus price target of $108.36, suggesting a potential downside of 5.61%. Charles River Laboratories International has a consensus price target of $246.69, suggesting a potential downside of 7.59%. Given Revvity's higher probable upside, research analysts clearly believe Revvity is more favorable than Charles River Laboratories International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	12 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Revvity has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Summary

Charles River Laboratories International beats Revvity on 10 of the 16 factors compared between the two stocks.

Get Charles River Laboratories International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRL vs. The Competition

Export

Metric	Charles River Laboratories International	Life Sciences Tools & Services Industry	Healthcare Sector	NYSE Exchange
Market Cap	$12.74B	$9.43B	$7.00B	$24.11B
Dividend Yield	N/A	1.45%	2.58%	3.69%
P/E Ratio	-55.04	63.08	270.58	29.19
Price / Sales	3.17	106.76	598.42	13.11
Price / Cash	12.19	26.16	28.89	19.37
Price / Book	4.15	5.09	11.18	4.91
Net Income	-$144.34M	$56.66B	$3.45B	$1.06B
7 Day Performance	15.77%	3.48%	3.37%	1.65%
1 Month Performance	14.18%	0.13%	-0.73%	2.63%
1 Year Performance	79.07%	22.30%	77.30%	20.40%

Charles River Laboratories International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRL Charles River Laboratories International	2.8096 of 5 stars	$266.95 -0.2%	$246.69 -7.6%	+79.1%	$12.74B	$4.02B	N/A	19,700	Earnings Report Analyst Forecast Gap Down
ICLR Icon	3.206 of 5 stars	$163.51 +4.2%	$170.40 +4.2%	+3.8%	$12.01B	$8.25B	38.38	40,100	Positive News
TECH Bio-Techne	2.7145 of 5 stars	$72.00 -0.1%	$68.08 -5.4%	+43.4%	$11.29B	$1.22B	104.35	3,100	Positive News Upcoming Earnings
A Agilent Technologies	4.4458 of 5 stars	$141.23 +1.5%	$159.35 +12.8%	+27.3%	$39.31B	$6.95B	28.36	18,100	Positive News Gap Down
IQV IQVIA	3.3537 of 5 stars	$236.07 +3.4%	$241.88 +2.5%	+32.2%	$37.56B	$16.98B	29.29	93,000	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CRL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Summary

How does Charles River Laboratories International compare to IQVIA?

Summary

How does Charles River Laboratories International compare to Revvity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Competitors

CRL vs. ICLR, TECH, A, IQV, and RVTY

How does Charles River Laboratories International compare to Icon?

Is ICLR or CRL more profitable?

Which has more volatility & risk, ICLR or CRL?

Does the media prefer ICLR or CRL?

Do insiders and institutionals have more ownership in ICLR or CRL?

Which has stronger valuation & earnings, ICLR or CRL?

Do analysts prefer ICLR or CRL?

Summary

How does Charles River Laboratories International compare to Bio-Techne?

Is TECH or CRL more profitable?

Does the media prefer TECH or CRL?

Which has preferable valuation and earnings, TECH or CRL?

Do analysts prefer TECH or CRL?

Which has more risk & volatility, TECH or CRL?

Do institutionals and insiders have more ownership in TECH or CRL?

Summary

How does Charles River Laboratories International compare to Agilent Technologies?

Which has more risk & volatility, A or CRL?

Do analysts recommend A or CRL?

Which has stronger earnings & valuation, A or CRL?

Do insiders & institutionals hold more shares of A or CRL?

Does the media prefer A or CRL?

Is A or CRL more profitable?

Summary

How does Charles River Laboratories International compare to IQVIA?

Does the media prefer IQV or CRL?

Is IQV or CRL more profitable?

Which has more risk & volatility, IQV or CRL?

Do analysts rate IQV or CRL?

Do insiders and institutionals hold more shares of IQV or CRL?

Which has stronger valuation and earnings, IQV or CRL?

Summary

How does Charles River Laboratories International compare to Revvity?

Does the media prefer RVTY or CRL?

Is RVTY or CRL more profitable?

Which has better earnings & valuation, RVTY or CRL?

Do institutionals & insiders hold more shares of RVTY or CRL?

Do analysts rate RVTY or CRL?

Which has more volatility & risk, RVTY or CRL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRL vs. The Competition

Charles River Laboratories International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools